Comprehensive self management and routine monitoring in chronic obstructive pulmonary disease patients in general practice: randomised controlled trial

Erik W M A Bischoff, Reinier Akkermans, Jean Bourbeau, Chris van Weel, Jan H Vercoulen, Tjard R J Schermer, Erik W M A Bischoff, Reinier Akkermans, Jean Bourbeau, Chris van Weel, Jan H Vercoulen, Tjard R J Schermer

Abstract

Objective: To assess the long term effects of two different modes of disease management (comprehensive self management and routine monitoring) on quality of life (primary objective), frequency and patients' management of exacerbations, and self efficacy (secondary objectives) in patients with chronic obstructive pulmonary disease (COPD) in general practice.

Design: 24 month, multicentre, investigator blinded, three arm, pragmatic, randomised controlled trial.

Setting: 15 general practices in the eastern part of the Netherlands.

Participants: Patients with COPD confirmed by spirometry and treated in general practice. Patients with very severe COPD or treated by a respiratory physician were excluded.

Interventions: A comprehensive self management programme as an adjunct to usual care, consisting of four tailored sessions with ongoing telephone support by a practice nurse; routine monitoring as an adjunct to usual care, consisting of 2-4 structured consultations a year with a practice nurse; or usual care alone (contacts with the general practitioner at the patients' own initiative).

Outcome measures: The primary outcome was the change in COPD specific quality of life at 24 months as measured with the chronic respiratory questionnaire total score. Secondary outcomes were chronic respiratory questionnaire domain scores, frequency and patients' management of exacerbations measured with the Nijmegen telephonic exacerbation assessment system, and self efficacy measured with the COPD self-efficacy scale.

Results: 165 patients were allocated to self management (n=55), routine monitoring (n=55), or usual care alone (n=55). At 24 months, adjusted treatment differences between the three groups in mean chronic respiratory questionnaire total score were not significant. Secondary outcomes did not differ, except for exacerbation management. Compared with usual care, more exacerbations in the self management group were managed with bronchodilators (odds ratio 2.81, 95% confidence interval 1.16 to 6.82) and with prednisolone, antibiotics, or both (3.98, 1.10 to 15.58).

Conclusions: Comprehensive self management or routine monitoring did not show long term benefits in terms of quality of life or self efficacy over usual care alone in COPD patients in general practice. Patients in the self management group seemed to be more capable of appropriately managing exacerbations than did those in the usual care group.

Trial registration: Clinical trials NCT00128765.

Conflict of interest statement

Competing interests: All authors have completed the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: no authors received any support from any company for the submitted work; no authors have any relationship with any company that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.

Figures

https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4790609/bin/bise005012.f1_default.jpg
Fig 1 Flow diagram of study. *Eligibility was assessed in general practice by measurement of pre-bronchodilator and post-bronchodilator lung function and collection of data on sociodemographic characteristics, smoking habits, current medical conditions, and current use of respiratory drugs. FEV1= forced expiratory volume in one second; FVC=forced vital capacity
https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4790609/bin/bise005012.f2_default.jpg
Fig 2 Changes in unadjusted means of chronic respiratory questionnaire total score during 24 months of follow-up for the self management, routine monitoring, and usual care groups. Bars indicate 95% CIs
https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4790609/bin/bise005012.f3_default.jpg
Fig 3 Percentages of patients with clinically important improvements (≥0.5 improvement from baseline) in chronic respiratory questionnaire (CRQ) total score during 24 months of follow-up

References

    1. Simpson CR, Hippisley-Cox J, Sheikh A. Trends in the epidemiology of chronic obstructive pulmonary disease in England: a national study of 51,804 patients. Br J Gen Pract 2010;60:277-84.
    1. Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: revised 2011. GOLD, 2011 (available from ).
    1. Bellamy D, Bouchard J, Henrichsen S, Johansson G, Langhammer A, Reid J, et al. International Primary Care Respiratory Group (IPCRG) guidelines: management of chronic obstructive pulmonary disease (COPD). Prim Care Respir J 2006;15:48-57.
    1. Van den Bemt L, Schermer T, Smeele I, Bischoff E, Jacobs A, Grol R, et al. Monitoring of patients with COPD: a review of current guidelines’ recommendations. Respir Med 2008;102:633-41.
    1. Bodenheimer T, Lorig K, Holman H, Grumbach K. Patient self-management of chronic disease in primary care. JAMA 2002;288:2469-75.
    1. Bandura A. The assessment and predictive generality of self-percepts of efficacy. J Behav Ther Exp Psychiatry 1982;13:195-9.
    1. Bourbeau J, Bischoff E, Sedeno MF. Self-management in prevention and early intervention of exacerbations. In: Wedzicha J, Martinez FJ, eds. Chronic obstructive pulmonary disease exacerbations. 1st ed. Informa Healthcare, 2008:357-68.
    1. Effing T, Monninkhof EM, Van der Valk PD, van der Palen J, van Herwaarden CL, Partridge MR, et al. Self-management education for patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2007;4:CD002990.
    1. Cranston JM, Crockett AJ, Moss JR, Pegram RW, Stocks NP. Models of chronic disease management in primary care for patients with mild-to-moderate asthma or COPD: a narrative review. Med J Aust 2008;188:S50-2.
    1. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. Eur Respir J 2005;26:319-38.
    1. Bourbeau J, Julien M, Maltais F, Rouleau M, Beaupre A, Begin R, et al. Reduction of hospital utilization in patients with chronic obstructive pulmonary disease: a disease-specific self-management intervention. Arch Intern Med 2003;163:585-91.
    1. Geijer RM, van Schayck CP, van Weel C, Sachs AP, Bottema BJ, Smeele IJ, et al. NHG-Standaard COPD: behandeling. Huisarts Wet 2001;44:207-19.
    1. National Institute for Clinical Excellence (NICE). Chronic obstructive pulmonary disease: national clinical guideline for management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax 2004;59(suppl I):i1-232.
    1. Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 1999;54:581-6.
    1. Puhan MA, Guyatt GH, Goldstein R, Mador J, McKim D, Stahl E, et al. Relative responsiveness of the chronic respiratory questionnaire, St. Georges respiratory questionnaire and four other health-related quality of life instruments for patients with chronic lung disease. Respir Med 2007;101:308-16.
    1. Schunemann HJ, Goldstein R, Mador MJ, McKim D, Stahl E, Puhan M, et al. A randomised trial to evaluate the self-administered standardised chronic respiratory questionnaire. Eur Respir J 2005;25:31-40.
    1. Redelmeier DA, Guyatt GH, Goldstein RS. Assessing the minimal important difference in symptoms: a comparison of two techniques. J Clin Epidemiol 1996;49:1215-9.
    1. Wigal JK, Creer TJ, Kotses H. The COPD self-efficacy scale. Chest 1991;99:1193-6.
    1. Bischoff EW, Boer LW, Molema J, Akkermans R, van Weel C, Vercoulen JH, et al. Validity of an automated telephonic system to assess COPD exacerbation rates. Eur Respir J 2012;39:1090-6.
    1. Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002;57:847-52.
    1. Seemungal TA, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;161:1608-13.
    1. Schermer T, Chavannes N, Dekhuijzen R, Wouters E, Muris J, Akkermans R, et al. Fluticasone and N-acetylcysteine in primary care patients with COPD or chronic bronchitis. Respir Med 2009;103:542-51.
    1. Suissa S. Statistical treatment of exacerbations in therapeutic trials of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006;173:842-6.
    1. Aaron SD, Fergusson D, Marks GB, Suissa S, Vandemheen K, Doucette S, et al. Counting, analyzing and reporting exacerbations of COPD in randomized, controlled trials. Thorax 2008;63:122-8.
    1. Bourbeau J, Nault D, Dang-Tan T. Self-management and behaviour modification in COPD. Patient Educ Couns 2004;52:271-7.
    1. Poels PJ, Schermer TR, van Weel C, Calverley PM. Spirometry in chronic obstructive pulmonary disease. BMJ 2006;333:870-1.
    1. Campbell MK, Elbourne DR, Altman DG, for the CONSORT Group. CONSORT statement: extension to cluster randomised trials. BMJ 2004;328:702-8.
    1. Van den Bemt L, Schermer T, Smeele I, Boonman-de Winter L, van Boxem TJ, Denis J, et al. An expert-supported monitoring system for patients with chronic obstructive pulmonary disease in general practice: results of a cluster randomised controlled trial. Med J Aust 2009;191:249-54.
    1. Lacasse Y, Goldstein R, Lasserson TJ, Martin S. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006;4:CD003793.
    1. Schermer T, Chavannes N, Dekhuijzen R, Wouters E, Muris J, Akkermans R, et al. Fluticasone and N-acetylcysteine in primary care patients with COPD or chronic bronchitis. Respir Med 2009;103:542-51.
    1. Rice K, Dewan N, Bloomfield H, Grill J, Schult T, Nelson D, et al. Disease management program for chronic obstructive pulmonary disease: a randomized controlled trial. Am J Respir Crit Care Med 2010;182:890-6.
    1. Bucknall C, Miller G, Lloyd S, Cleland J, McCluskey S, Cotton M, et al. Glasgow supported self-management trial (GSuST) for patients with moderate to severe COPD: randomised controlled trial. BMJ 2012;344:e1060.
    1. Kara M, Asti T. Effect of education on self-efficacy of Turkish patients with chronic obstructive pulmonary disease. Patient Educ Couns 2004;55:114-20.
    1. Bischoff EW, Hamd DH, Sedeno MF, Benedetti A, Schermer TR, Bernard S, et al. Effects of written action plan adherence on COPD exacerbation recovery. Thorax 2011;66:26-31.
    1. Langsetmo L, Platt RW, Ernst P, Bourbeau J. Underreporting exacerbation of chronic obstructive pulmonary disease in a longitudinal cohort. Am J Respir Crit Care Med 2008;177:396-401.
    1. Wilkinson TM, Donaldson GC, Hurst JR, Seemungal TA, Wedzicha JA. Early therapy improves outcomes of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004;169:1298-303
    1. Adams SG, Smith PK, Allan PF, Anzueto A, Pugh JA, Cornell JE. Systematic review of the chronic care model in chronic obstructive pulmonary disease. Arch Intern Med 2007;167:551-61.

Source: PubMed

3
구독하다